Open main menu
Home
Random
Recent changes
Special pages
Community portal
Preferences
About Wikipedia
Disclaimers
Incubator escapee wiki
Search
User menu
Talk
Dark mode
Contributions
Create account
Log in
Editing
Cachexia
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
==== Staging ==== * Non-cachexia (0-2 points) - No major weight loss or problems with appetite.<ref name="nishikawa-2021" /> * Pre-cachexia (3-4 points) - Mild weight loss and appetite issues. Early treatment at this stage might slow progression of cachexia.<ref name="nishikawa-2021" /> * Cachexia (5-8 points) - Significant muscle loss that is difficult to reverse and affects daily function.<ref>{{Cite journal |last=Arends |first=J. |last2=Baracos |first2=V. |last3=Bertz |first3=H. |last4=Bozzetti |first4=F. |last5=Calder |first5=P.C. |last6=Deutz |first6=N.E.P. |last7=Erickson |first7=N. |last8=Laviano |first8=A. |last9=Lisanti |first9=M.P. |last10=Lobo |first10=D.N. |last11=McMillan |first11=D.C. |last12=Muscaritoli |first12=M. |last13=Ockenga |first13=J. |last14=Pirlich |first14=M. |last15=Strasser |first15=F. |date=October 2017 |title=ESPEN expert group recommendations for action against cancer-related malnutrition |url=https://linkinghub.elsevier.com/retrieve/pii/S0261561417302285 |journal=Clinical Nutrition |language=en |volume=36 |issue=5 |pages=1187β1196 |doi=10.1016/j.clnu.2017.06.017}}</ref> * Refractory cachexia (9-12 points) - Severe weight and muscle loss with poor response to treatment and a life expectancy of less than 3 months.<ref name="nishikawa-2021" /> The ''Cachexia SCOre (CASCO)'' is another scoring system that looks at weight loss, inflammation, metabolism, immune function, physical ability, appetite, and quality of life to provide a more detailed assessment.<ref name="dev-2019" />
Edit summary
(Briefly describe your changes)
By publishing changes, you agree to the
Terms of Use
, and you irrevocably agree to release your contribution under the
CC BY-SA 4.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)